The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis

Constitutive activation of JAK2/STAT3 is a major oncogenic signaling event involved in the development of Burkitt lymphoma (BL). In the present study, we investigated the antilymphoma activity of TG101209, a specific JAK2 inhibitor, on EBV-positive and EBV-negative Burkitt lymphoma cell lines and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yang, Li, Ji, Zhong, Haiying, Xiao, Xiang, Wang, Zhihua, Cheng, Zhao, Hu, Cunhong, Zhang, Guangsen, Liu, Sufang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481535/
https://www.ncbi.nlm.nih.gov/pubmed/34588425
http://dx.doi.org/10.1038/s41420-021-00655-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481535/
https://www.ncbi.nlm.nih.gov/pubmed/34588425
http://dx.doi.org/10.1038/s41420-021-00655-1

Ejemplares similares